INCY Quote, Financials, Valuation and Earnings

Gilead Sciences has a net margin of 15.03% compared to Incyte's net margin of 19.72%. Incyte's return on equity of 0.57% beat Gilead Sciences's return on equity of 32.29%.

Incyte has a consensus price target of $73.80, signalling upside risk potential of 25.12%. On the other hand Gilead Sciences has an analysts' consensus of $115.04 which suggests that it could grow by 18.71%. Given that Incyte has higher upside potential than Gilead Sciences, analysts believe Incyte is more attractive than Gilead Sciences.

Incyte has a beta of 0.676, which suggesting that the stock is 32.409% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.263, suggesting its less volatile than the S&P 500 by 73.697%.

Incyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences offers a yield of 3.2% to investors and pays a quarterly dividend of $0.79 per share. Incyte pays -- of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend.

Incyte quarterly revenues are $1.1B, which are smaller than Gilead Sciences quarterly revenues of $6.7B. Incyte's net income of $158.2M is lower than Gilead Sciences's net income of $1.3B. Notably, Incyte's price-to-earnings ratio is 184.31x while Gilead Sciences's PE ratio is 20.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Incyte is 2.74x versus 4.25x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 15.03% compared to Incyte's net margin of 21.68%. Incyte's return on equity of 0.57% beat Eli Lilly and's return on equity of 78.25%.

Incyte has a consensus price target of $73.80, signalling upside risk potential of 25.12%. On the other hand Eli Lilly and has an analysts' consensus of $978.82 which suggests that it could grow by 33.25%. Given that Eli Lilly and has higher upside potential than Incyte, analysts believe Eli Lilly and is more attractive than Incyte.

Incyte has a beta of 0.676, which suggesting that the stock is 32.409% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.479, suggesting its less volatile than the S&P 500 by 52.104%.

Incyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.74% to investors and pays a quarterly dividend of $1.50 per share. Incyte pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Incyte quarterly revenues are $1.1B, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Incyte's net income of $158.2M is lower than Eli Lilly and's net income of $2.8B. Notably, Incyte's price-to-earnings ratio is 184.31x while Eli Lilly and's PE ratio is 59.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Incyte is 2.74x versus 13.54x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Natera has a net margin of 15.03% compared to Incyte's net margin of -13.34%. Incyte's return on equity of 0.57% beat Natera's return on equity of -19.19%.

Incyte has a consensus price target of $73.80, signalling upside risk potential of 25.12%. On the other hand Natera has an analysts' consensus of $189.01 which suggests that it could grow by 24.39%. Given that Incyte has higher upside potential than Natera, analysts believe Incyte is more attractive than Natera.

Incyte has a beta of 0.676, which suggesting that the stock is 32.409% less volatile than S&P 500. In comparison Natera has a beta of 1.794, suggesting its more volatile than the S&P 500 by 79.445%.

Incyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Natera offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Incyte pays -- of its earnings as a dividend. Natera pays out -- of its earnings as a dividend.

Incyte quarterly revenues are $1.1B, which are larger than Natera quarterly revenues of $501.8M. Incyte's net income of $158.2M is higher than Natera's net income of -$66.9M. Notably, Incyte's price-to-earnings ratio is 184.31x while Natera's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Incyte is 2.74x versus 10.64x for Natera. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of 15.03% compared to Incyte's net margin of 26.7%. Incyte's return on equity of 0.57% beat Regeneron Pharmaceuticals's return on equity of 15.7%.

Incyte has a consensus price target of $73.80, signalling upside risk potential of 25.12%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $800.13 which suggests that it could grow by 51.6%. Given that Regeneron Pharmaceuticals has higher upside potential than Incyte, analysts believe Regeneron Pharmaceuticals is more attractive than Incyte.

Incyte has a beta of 0.676, which suggesting that the stock is 32.409% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.331%.

Incyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.17% to investors and pays a quarterly dividend of $0.88 per share. Incyte pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Incyte quarterly revenues are $1.1B, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3B. Incyte's net income of $158.2M is lower than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Incyte's price-to-earnings ratio is 184.31x while Regeneron Pharmaceuticals's PE ratio is 13.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Incyte is 2.74x versus 4.28x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.